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1100-60 Platelet Dysfunction Following a 300 mg Clopidogrel 
Loading Dose in Type 2 Diabetes Undergoing Coronary 
Stenting
Dominick J. Angiolillo, Antonio Fernández-Ortíz, Esther Bernardo, Celia Ramírez, Manel 
Sabaté, Rosana Hernández-Antolín, Raul Moreno, Fernando Alfonso, Javier Escaned, 
Camino Bañuelos, Carlos Macaya, Cardiovascular Institute-San Carlos University 
Hospital, Madrid, Spain
Background: A 300 mg clopidogrel loading dose (LD) is currently recommended to
reduce the early risk of stent thrombosis (ST). However, ST still occurs and most fre-
quently in patients with type 2 diabetes (D). Aim of this study was to compare platelet
aggregation (PA) in D with that of non-diabetic (ND) patients undergoing coronary stent-
ing (CS) receiving a 300 mg clopidogrel LD. Methods: We studied a total number of 48
pts undergoing CS receiving a 300 mg clopidogrel LD at intervention time. All pts were on
aspirin (100mg/d) and were treated with clopidogrel (75 mg/d) for one month. Patients
receiving GP IIb/IIIa blockers were not included. Diabetic status was defined according to
WHO criteria. PA was assessed by light transmittance following ADP-stimuli (6µM) at
baseline (B), and 4 hours and 24 following CS. Results (mean±SD): In the overall study
population, 13/48 (27%) were D and 35/48 (73%) were ND. D had a higher degree of PA
at B (63±22 vs 52±15; p=0.05) and a lower response to clopidogrel LD at 4 (51±18 vs
37±14; p=0.007) and 24 (42±22 vs 30±17; p=0.05) hours. Furthermore, PA was signifi-
cantly higher (p=0.004) in D during the overall study time course by MANOVA analysis
(Figure). Conclusion: D have a higher degree of PA when only on aspirin treatment
(confirming data from previous studies) and a lower response to a standard 300 mg clopi-
dogrel LD. This may explain the increased early risk of ST in D and suggest the use of a
higher clopidogrel LD in these patients. 
1100-61 Effect of a 600 mg Clopidogrel Loading Dose on Platelet 
Function in Patients Undergoing Coronary Stenting
Dominick J. Angiolillo, Antonio Fernández-Ortiz, Esther Bernardo, Celia Ramirez, Manel 
Sabate, Rosana Hernández-Antolín, Javier Escaned, Fernando Alfonso, Camino 
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Hospital, Madrid, Spain
Background: A 300 mg clopidogrel loading dose (LD) is currently used to reduce the
early risk of stent thrombosis. Since a variable interindividual response to such regimen
has been described, a higher LD is suggested to optimize antiplatelet effects. The aim of
the study was to compare platelet function in pts undergoing coronary stenting (CS) and
receiving a 300 mg or 600 mg clopidogrel LD. Methods: We studied 40 pts receiving a
300 mg (LD-300, n=20) or 600 mg clopidogrel LD (LD-600, n=20) at intervention time. All
pts were on aspirin (100mg/d) and treated with clopidogrel (75 mg/d) for 1 month. Platelet
aggregation (PA) was assessed by light transmittance aggregometry in ADP (6µM) stim-
ulated platelets, and platelet GPIIb/IIIa activation was assessed by whole blood flow
cytometry using anti-fibrinogen (AFB) polyclonal antibodies following ADP (2 µM) stimuli
at baseline (B), 4 hrs, 24 hrs and 48 hrs following CS. Results (mean±SD): Although no
differences were found in ADP-induced PA between 300-LD and 600-LD pts at any time
point (table), an earlier and a greater inhibition on ADP-induced GPIIb/IIIa activation was
achieved in 600-LD pts during overall study time course (p=0.001; MANOVA). There
were no differences in bleeding complications. Conclusion: Although a 600 mg clopi-
dogrel LD does not increase inhibition of ADP-induced PA compared to a 300 mg LD, it
confers a more rapid and extensive inhibition of GPIIb/IIIa activation early after CS sug-
gesting a more effective protection against early thrombotic risk.
1100-62 Superior Early Platelet Inhibition by 600mg Clopidogrel 
Loading in Elective Stenting
Paul A. Gurbel, Bonnie L. Hiatt, Meinrad Gawaz, Sinai Center for Thrombosis Research, 
Baltimore, MD, Deutsches Herzzentrum und I. Medizinische Klinik, Munich, Germany
BACKGROUND: The optimal clopidogrel loading regimen remains controversial. The
most widely prescribed dose in the United States is 300 mg. A previous small European
study suggested superior inhibition with 600 mg.
METHODS: Platelet aggregation by light transmittance aggregometry using 5 and 20
microM ADP was studied in 196 patients in 2 centers. Patients received either 600 mg (
group A) or 300 mg ( group B ) within 1 hour of stenting. Platelet aggregation was mea-
sured at 2-4 hours and 24 hours after stenting. GP IIb/IIIa inhibitors were withheld per
protocol.
RESULTS: Baseline aggregation to 5 and 20 microM was the same in both groups (
table). Aggregation at 2-4 hours post-stenting was reduced in Group A compared to
Group B ( p< .05). At 24 hours there was marked reduction in aggregation in Group A [17
% ( 5 microM ADP), 35 % ( 20 MicroM ADP )] versus Group B [ 37 % ( 5microM ADP ),
60 % ( 20 micro M ADP)].* p < .05 Group A vs Group B.
CONCLUSION: There is more complete and rapid platelet inhibition with a clopidogrel
loading dose of 600 mg as compared to 300 mg when administered within one hour of
elective stenting. This higher dose regimen should be studied in relation to patient out-
comes in a larger scale clinical trial.
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1101-41 Intravascular Ultrasound Assessment of Lesions With 
Sirolimus-Eluting Stent Failure
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Roxana Mehran, David Jacoboff, George D. Dangas, Alexandra J. Lansky, Issam 
Moussa, Michael B. Collins, Edward Kreps, Gregg W. Stone, Martin B. Leon, Jeffrey W. 
Moses, Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, 
New York, NY
Background: Little intravascular ultrasound (IVUS) information is available in patients
with sirolimus-eluting stent (SES) failure.
Methods and Results: IVUS was performed in 33 lesions of 23 patients with SES failure
[30% diabetic patients and 26% brachytherapy failure]. (1) There were 2 subacute and 1
late thromboses that resulted in myocardial infarction (n=2) and death (n=1); stent under-
expansion was identified in 2 patients, residual edge dissection in 1, and residual edge
stenosis in 1. (2) In 1 lesion, follow-up IVUS revealed no stent. In this case post-stent
IVUS showed significant stent protrusion into the aorta; we speculate that stent embo-
lization might have occurred during disengagement of the guiding catheter. (3) In 3
patients, there was a new stenosis within the adjacent reference segment, but not at the
edge. (4) SES in-stent restenosis (ISR) was observed in 25 lesions, including 5 edge res-
tenoses. Pre-SES lesion morphology included 5 bifurcations, 2 ostial lesions and 1 total
occlusion. A gap between stents was shown in 4 ISR lesions (16%); and stent underex-
pansion was identified in 50% [especially, in 4/5 bifurcation lesions (Fig.A)]. Both nega-
tive remodeling (Fig.B) and intimal hyperplasia (Fig.C) were observed in 5 stent edge
ISR.
Conclusions: The most common IVUS finding in SES failure is stent underexpansion.
However, other findings are also seen including gaps between multiple stents, new
stenosis formation, and negative remodeling and intimal hyperplasia at edge restenosis.
B 4 hours 24 hours 48 hours
LD-300(PA) 57±21 39±17 27±12 29±11
LD-600(PA) 63±9 42±13 28±14 31±13
p NS NS NS NS
LD-300(AFB) 63±26 60±30 46±25 41±25
LD-600(AFB) 58±27 20±18 25±16 18±16
p NS <0.0001 0.008 0.005
Aggregation (%)
Group A Group B
5 microM ADP 20 microM ADP 5microM ADP 20 microM ADP
Baseline 65 79 62 83
2-4 hours 22* 42* 58 80
24 hours 17* 35* 37 60
